Stock Events

Stock Events

Lisata Therapeutics 

€4.18
0
-€0.02-0.48% Today

Statistics

Day High
4.24
Day Low
4.16
52W High
4.24
52W Low
1.55
Volume
0
Avg. Volume
13
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q4 2025
Next
-0.44
-0.11
0.22
0.56
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 8NE.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.49B
BioMarin Pharmaceutical develops and commercializes innovative therapies for rare genetic diseases, overlapping with Lisata's focus on novel treatments.
Alnylam Pharmaceuticals
ALNY
Mkt Cap42.72B
Alnylam Pharmaceuticals focuses on RNAi therapeutics for genetically defined diseases, competing in the genetic disorder treatment space.
Sarepta Therapeutics
SRPT
Mkt Cap2.22B
Sarepta Therapeutics is involved in the discovery and development of RNA-based therapeutics, targeting conditions similar to those Lisata aims at.
Vertex Pharmaceuticals
VRTX
Mkt Cap110.97B
Vertex Pharmaceuticals concentrates on creating new treatments for cystic fibrosis and other serious diseases, potentially competing in therapeutic areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap79.17B
Regeneron Pharmaceuticals is known for its innovative biologics, directly competing in the biopharmaceutical space for rare diseases.
Biogen
BIIB
Mkt Cap25.38B
Biogen focuses on neurology, rare diseases, and autoimmune conditions, areas that might overlap with Lisata's therapeutic targets.
AMGEN
AMGN
Mkt Cap189.22B
Amgen is a biotech giant with a broad portfolio that includes treatments for serious illnesses, possibly competing in some areas.
Gilead Sciences
GILD
Mkt Cap172.51B
Gilead Sciences has a diverse range of products, including for rare diseases, which could place it in competition with Lisata.
Novo Nordisk
NVO
Mkt Cap167.44B
Novo Nordisk specializes in diabetes care and other serious chronic conditions, potentially competing in the broader healthcare market.
Pfizer
PFE
Mkt Cap153.13B
Pfizer has a wide-ranging portfolio that includes treatments for rare diseases and other serious conditions, making it a competitor in various therapeutic areas.

About

Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in development of cell therapies for select cardiovascular and autoimmune diseases. The company is headquartered in Basking Ridge, New Jersey and currently employs 25 full-time employees. The Company’s product candidates include three developmental treatments for cardiovascular diseases based on its classification determinant34+ (CD34+) cell therapy platform. Its CLBS12 product candidate is a recipient of a SAKIGAKE designation in Japan and advanced therapy medicinal product classification (ATMP) in Europe. Its CLBS16 product candidate is being developed for the treatment of coronary microvascular dysfunction (CMD). Its CLBS14 product candidate is a phase III ready clinical program in no option refractory disabling angina. CLBS14 is a recipient of a regenerative medicine advanced therapy (RMAT) designation in the United States. The company also has an autoimmune product candidate, CLBS03, which is being developed for the treatment of type I diabetes.
Show more...
CEO
David Mazzo
Employees
24
Country
United States
ISIN
US1280583022

Listings

LSE
GB
0HS8.LSE
MU
DE
8NE.MU
STU
DE
8NE.STU
F
DE
8NE.F

0 Comments

Share your thoughts

FAQ

What is Lisata Therapeutics stock price today?▼
The current price of 8NE.STU is €4.18 EUR — it has decreased by -0.48% in the past 24 hours. Watch Lisata Therapeutics stock price performance more closely on the chart.
What is Lisata Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Lisata Therapeutics stocks are traded under the ticker 8NE.STU.
Is Lisata Therapeutics stock price growing?▼
8NE.STU stock has fallen by -1.87% compared to the previous week, the month change is a -3.23% fall, over the last year Lisata Therapeutics has showed a +151.5% increase.
When is the next Lisata Therapeutics earnings date?▼
Lisata Therapeutics is going to release the next earnings report on May 07, 2026.
How many employees does Lisata Therapeutics have?▼
As of April 13, 2026, the company has 24 employees.
In which sector is Lisata Therapeutics located?▼
Lisata Therapeutics operates in the Manufacturing sector.
When did Lisata Therapeutics complete a stock split?▼
Lisata Therapeutics has not had any recent stock splits.
Where is Lisata Therapeutics headquartered?▼
Lisata Therapeutics is headquartered in Basking Ridge, United States.